Sobi To Start Selling Zynlonta After Sealing EU Approval
High Hopes For Lymphoma Drug
Five months after paying $55m upfront to Switzerland's ADC Therapeutics, Sobi has been granted conditional marketing authorization for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
